TRODELVY® (sacituzumab Govitecan-hziy) | Patient And …
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with: triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for …
Sacituzumab Govitecan-hziy - National Cancer Institute
TRODELVY® (sacituzumab govitecan-hziy) | Patient and Caregiver Home
Sacituzumab Govitecan-hziy: An Antibody-Drug …
TRODELVY® (sacituzumab govitecan-hziy) | For Patients
Sacituzumab Govitecan-hziy (Trodelvy) - Drug …
TRODELVY® (sacituzumab govitecan-hziy) Access Support | For Patients
Sacituzumab Govitecan-hziy In Refractory Metastatic …
TRODELVY® (sacituzumab govitecan-hziy) Side Effects|For Patients
Sacituzumab Govitecan For Metastatic Triple‐Negative …
Sacituzumab govitecan-hziy is also being studied in the treatment of other types of cancer. More About Sacituzumab Govitecan-hziy. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. MedlinePlus Information on Sacituzumab Govitecan-hziy - A lay language summary of important information about this drug that may …
Trodelvy (sacituzumab Govitecan): Side Effects, How It …
Keywords included sacituzumab govitecan (-hziy), IMMU-132, Trop-2 (trophoblast cell-surface antigen 2), and TACSTD2. Study selection and data extraction: All English-language trials involving sacituzumab govitecan for mTNBC were included and discussed. Data synthesis: Sacituzumab govitecan is an antibody-drug conjugate targeted for Trop-2 and conjugated to …
TRODELVY® (sacituzumab Govitecan-hziy) | Official HCP …
Sacituzumab govitecan-hziy is composed of a Trop-2-directed humanized antibody and SN-38, a topoisomerase I inhibitor, attached by a linker. Sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized into the cell. SN-38 is released into the cancer cell by breaking the linker. SN-38 interacts with topoisomerase I, resulting in DNA damage and cell …
Sacituzumab Govitecan-hziy In Refractory Metastatic …
Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. Methods: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of …
Sacituzumab Govitecan - Wikipedia
10/07/2021 · The accelerated approval of sacituzumab govitecan‐hziy (TRODELVY) in April 2020 marked a breakthrough in breast cancer therapy as one of the few targeted therapy options currently available for TNBC. However, given its recent approval, there is limited experience using this drug in a clinical setting and, in particular, with managing adverse events. The aim of this …